Expression of CD52 in peripheral T-cell lymphoma

被引：48
|
作者：
Piccaluga, Pier Paolo [1 ]
Agostinelli, Claudio [1 ]
Righi, Simona [1 ]
Zinzani, Pier Luigi [1 ]
Pileri, Stefano A. [1 ]
机构：
[1] Univ Bologna, Inst Hematol & Med Oncol L&A Seragnoli, S Orsola Malpighi Hosp, I-40138 Bologna, Italy
来源：
HAEMATOLOGICA | 2007年 / 92卷 / 04期
关键词：
T-cell lymphoma; CD52; expression;
D O I：
10.3324/haematol.10767
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Peripheral T-cell lymphoma unspecified (PTCL/U) is a rare tumor characterized by poor treatment response and a dismal prognosis. We studied CD52 expression in 97 PTCL/U cases by immunohistochemistry on tissue-microarrays. Furthermore, CD52 gene expression was studied in 28 cases for which RNA was available. We found that CD52 is expressed in approximately 40% of PTCLs/U at the same level as in normal T-lymphocytes. Although other factors may play a role in the in vivo response to alemtuzumab, an anti-CD52 monoclonal antibody, the estimation of CD52 expression may provide a rationale for the selection of patients with a higher probability of treatment response.
引用
收藏
页码：566 / 567
页数：2
相关论文
共 50 条
  • [1] CD52 expression in mantle cell lymphoma
    Bass, AJ
    Gong, J
    Nelson, R
    Rizzieri, DA
    LEUKEMIA & LYMPHOMA, 2002, 43 (02) : 339 - 342
  • [2] Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma
    Dunleavy, Kieron
    Wilson, Wyndham H.
    LEUKEMIA & LYMPHOMA, 2010, 51 (09) : 1583 - 1584
  • [3] CD52 Expression in T Cell Lymphomas
    Ghorab, Z.
    Wong, J. W.
    Buckstein, R.
    Cheung, M.
    Nofech-Mozes, S.
    MODERN PATHOLOGY, 2009, 22 : 263A - 264A
  • [4] CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies
    Geissinger, Eva
    Bonzheim, Irina
    Roth, Sabine
    Rosenwald, Andreas
    Mueller-Hermelink, Hans Konrad
    Ruediger, Thomas
    LEUKEMIA & LYMPHOMA, 2009, 50 (06) : 1010 - 1016
  • [5] CD52 expression in non-mycotic T- and NK/T-cell lymphomas
    Chang, Sheng-Tsung
    Lu, Chin-Li
    Chuang, Shih-Sung
    LEUKEMIA & LYMPHOMA, 2007, 48 (01) : 117 - 121
  • [6] CD52 expression in T-cell large granular lymphocyte leukemia - Implications for treatment with alemtuzumab
    Osuji, N
    Del Giudice, I
    Matutes, E
    Morilla, A
    Owusu-Ankomah, K
    Morilla, R
    Dunlop, A
    Catovksy, D
    LEUKEMIA & LYMPHOMA, 2005, 46 (05) : 723 - 727
  • [7] Treatment of T-cell prolymphocytic leukemia with human CD52 antibody
    Pawson, R
    Dyer, MJS
    Barge, R
    Matutes, E
    Thornton, PD
    Emmett, E
    KluinNelemans, JC
    Fibbe, WE
    Willemze, R
    Catovsky, D
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) : 2667 - 2672
  • [8] Lack of evidence for T-cell expression of siglec-10 and suppressive interaction with soluble CD52
    Azzopardi, L.
    Havari, E.
    Turner, M.
    Brondyk, W.
    Reczek, D.
    Georgieva, Z.
    Siders, W.
    Kaplan, J.
    Roberts, B.
    Coles, A. J.
    Jones, J.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 547 - 547
  • [9] Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia
    Tuset, E
    Matutes, E
    Brito-Babapulle, V
    Morilla, R
    Catovsky, D
    LEUKEMIA & LYMPHOMA, 2001, 42 (06) : 1379 - 1383
  • [10] CD52 expression in hairy cell leukemia
    Quigley, MM
    Bethel, KJ
    Sharpe, RW
    Saven, A
    AMERICAN JOURNAL OF HEMATOLOGY, 2003, 74 (04) : 227 - 230
12345